XOMA Royalty (XOMA) Non-cash Items (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Non-cash Items came in at $22.1 million in Q1 2026, up 167.44% year-on-year from $8.3 million in Q1 2025, and up 52.25% quarter-over-quarter from $14.5 million in Q4 2025.
XOMA Royalty (XOMA) Non-cash Items (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Non-cash Items across 17 years of filings, most recently posting $22.1 million for Q1 2026.
- Non-cash Items for Q1 2026 came in at $22.1 million, up 167.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.1 million (up 167.44% YoY), and the FY2025 annual result was $14.5 million, up 606.83% from the prior year.
- Non-cash Items came in at $22.1 million for Q1 2026 at XOMA Royalty, up from $14.5 million in the prior quarter.
- In the past five years, Non-cash Items ranged from a high of $22.1 million in Q1 2026 to a low of $1.5 million in Q1 2022.
- The 5-year median for Non-cash Items is $8.3 million (2025), against an average of $8.5 million.
- Across the five-year window, Non-cash Items slumped 96.63% in 2022 and soared 893.81% in 2023, its largest moves.
- XOMA Royalty's Non-cash Items stood at $10.8 million in 2022, then decreased by 1.54% to $10.6 million in 2023, then surged by 75.26% to $18.6 million in 2024, then retreated by 22.12% to $14.5 million in 2025, then jumped by 52.25% to $22.1 million in 2026.
- The last three Non-cash Items figures came in at $22.1 million (Q1 2026), $14.5 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.11 Mn |
| Mar 31, 2026 | 22.11 Mn |
| Dec 31, 2025 | 14.52 Mn |
| Dec 31, 2025 | 14.52 Mn |
| Sep 30, 2025 | 2.02 Mn |
| Sep 30, 2025 | 2.02 Mn |
| Jun 30, 2025 | 2.09 Mn |
| Jun 30, 2025 | 2.09 Mn |
| Mar 31, 2025 | 8.27 Mn |
| Mar 31, 2025 | 8.27 Mn |
| Dec 31, 2024 | 18.64 Mn |
| Dec 31, 2024 | 18.64 Mn |
| Sep 30, 2024 | 2.04 Mn |
| Sep 30, 2024 | 2.04 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Mar 31, 2024 | 17.72 Mn |
| Mar 31, 2024 | 17.72 Mn |
| Dec 31, 2023 | 10.64 Mn |
| Dec 31, 2023 | 10.64 Mn |